Can-Fite BioPharma Ltd.
Clinical-stage biopharma developing oral small-molecule drugs targeting the A3AR.
CANF | TA
Overview
Corporate Details
- ISIN(s):
- IL0010944739 (+2 more)
- LEI:
- 549300ZLRH6GSBOHFZ59
- Country:
- Israel
- Address:
- PO BOX 7537, 4917000 PETACH-TIKVA
- Website:
- https://www.canfite.com/
- Sector:
- Manufacturing
Description
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company with integrated drug discovery and development capabilities. The company specializes in creating orally bioavailable small-molecule drugs. Its proprietary platform technology is centered on the A3 adenosine receptor (A3AR), a therapeutic target highly expressed in cancer and inflammatory cells but minimally in normal cells. Can-Fite's compounds bind to A3AR to initiate anti-cancer and anti-inflammatory effects by modulating cellular signal transduction pathways. The company's advanced pipeline features proprietary drug candidates in Phase II and Phase III clinical development for treating oncology, inflammatory, liver, and metabolic diseases. A lead drug, Namodenoson, is in a pivotal Phase III study for advanced liver cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2023-06-24 01:28 |
NOTICE OF 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 31, 20…
|
English | HTM • 36.0 KB | ||
| 2023-06-13 16:08 |
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Nam…
|
English | PDF • 141.6 KB | ||
| 2023-06-13 16:08 |
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Nam…
|
English | HTM • 36.1 KB | ||
| 2023-06-01 15:59 |
1 Reports First Quarter 2023 Financial Results & Provides Clinical Update
|
English | PDF • 173.9 KB | ||
| 2023-06-01 15:59 |
1 Reports First Quarter 2023 Financial Results & Provides Clinical Update
|
English | HTM • 36.1 KB | ||
| 2023-05-30 15:59 |
Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the …
|
English | PDF • 177.7 KB | ||
| 2023-05-30 15:59 |
Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the …
|
English | HTM • 36.2 KB | ||
| 2023-05-09 15:59 |
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic C…
|
English | PDF • 158.4 KB | ||
| 2023-05-09 15:59 |
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic C…
|
English | HTM • 36.3 KB | ||
| 2023-05-02 15:59 |
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action
…
|
English | PDF • 159.8 KB | ||
| 2023-05-02 15:59 |
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action
…
|
English | HTM • 36.4 KB | ||
| 2023-04-24 15:59 |
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves To…
|
English | PDF • 157.6 KB | ||
| 2023-04-24 15:59 |
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves To…
|
English | HTM • 36.2 KB | ||
| 2023-04-22 01:14 |
FORM S-8-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
|
English | PDF • 177.6 KB | ||
| 2023-04-22 01:14 |
FORM S-8-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
|
English | HTM • 36.1 KB |
Automate Your Workflow. Get a real-time feed of all Can-Fite BioPharma Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Can-Fite BioPharma Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Can-Fite BioPharma Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
